ZA992549B - Incorporation of active substances in carrier matrixes. - Google Patents

Incorporation of active substances in carrier matrixes.

Info

Publication number
ZA992549B
ZA992549B ZA9902549A ZA992549A ZA992549B ZA 992549 B ZA992549 B ZA 992549B ZA 9902549 A ZA9902549 A ZA 9902549A ZA 992549 A ZA992549 A ZA 992549A ZA 992549 B ZA992549 B ZA 992549B
Authority
ZA
South Africa
Prior art keywords
incorporation
active substances
carrier matrixes
matrixes
carrier
Prior art date
Application number
ZA9902549A
Other languages
English (en)
Inventor
Marie-Louise Andersson
Catherine Boissier
Anne Mari Juppo
Anette Larsson
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of ZA992549B publication Critical patent/ZA992549B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/04—Solvent extraction of solutions which are liquid
    • B01D11/0403—Solvent extraction of solutions which are liquid with a supercritical fluid
    • B01D11/0411—Solvent extraction of solutions which are liquid with a supercritical fluid the supercritical fluid acting as solvent for the solvent and as anti-solvent for the solute, e.g. formation of particles from solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]
    • Y10T428/2985—Solid-walled microcapsule from synthetic polymer

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Catalysts (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Nozzles (AREA)
  • General Preparation And Processing Of Foods (AREA)
ZA9902549A 1998-04-14 1999-04-06 Incorporation of active substances in carrier matrixes. ZA992549B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9801287A SE9801287D0 (sv) 1998-04-14 1998-04-14 Incorporation of active substances in carrier matrixes

Publications (1)

Publication Number Publication Date
ZA992549B true ZA992549B (en) 1999-10-14

Family

ID=20410946

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9902549A ZA992549B (en) 1998-04-14 1999-04-06 Incorporation of active substances in carrier matrixes.

Country Status (31)

Country Link
US (1) US6372260B1 (pt)
EP (1) EP1069890B1 (pt)
JP (1) JP2002511400A (pt)
KR (1) KR100600691B1 (pt)
CN (1) CN1201728C (pt)
AR (1) AR019262A1 (pt)
AT (1) ATE329580T1 (pt)
AU (1) AU744874B2 (pt)
BR (1) BR9909636A (pt)
CA (1) CA2327522C (pt)
CY (1) CY1105154T1 (pt)
CZ (1) CZ20003784A3 (pt)
DE (1) DE69931904T2 (pt)
DK (1) DK1069890T3 (pt)
EE (1) EE200000595A (pt)
ES (1) ES2267268T3 (pt)
HU (1) HUP0102305A3 (pt)
ID (1) ID29286A (pt)
IL (1) IL138635A0 (pt)
IS (1) IS5656A (pt)
NO (1) NO329145B1 (pt)
NZ (1) NZ507190A (pt)
PL (1) PL344077A1 (pt)
PT (1) PT1069890E (pt)
RU (1) RU2208435C2 (pt)
SE (1) SE9801287D0 (pt)
SK (1) SK14112000A3 (pt)
TR (1) TR200002960T2 (pt)
TW (1) TW542724B (pt)
WO (1) WO1999052507A1 (pt)
ZA (1) ZA992549B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6669960B2 (en) * 1999-12-21 2003-12-30 Rxkinetix, Inc. Particulate drug-containing products and method of manufacture
US6761909B1 (en) * 1999-12-21 2004-07-13 Rxkinetix, Inc. Particulate insulin-containing products and method of manufacture
GB0102075D0 (en) 2001-01-26 2001-03-14 Astrazeneca Ab Process
FR2824754B1 (fr) * 2001-05-15 2004-05-28 Separex Sa Procede d'obtention de particules solides a partir d'au moins un produit hydrosoluble
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
US20070098784A1 (en) 2001-09-28 2007-05-03 Nutraceutix, Inc. Delivery system for biological component
KR100979877B1 (ko) * 2001-09-28 2010-09-02 뉴트라슈틱스 인코포레이티드 생물학적 성분의 전달 시스템
US20050048077A1 (en) * 2002-02-21 2005-03-03 George Sachs Compositions, test kits and methods for detecting helicobacter pylori
US6998051B2 (en) * 2002-07-03 2006-02-14 Ferro Corporation Particles from supercritical fluid extraction of emulsion
GB0216780D0 (en) * 2002-07-19 2002-08-28 Bradford Particle Design Ltd Methods of particle formation
US6966990B2 (en) 2002-10-11 2005-11-22 Ferro Corporation Composite particles and method for preparing
US6931888B2 (en) * 2003-02-07 2005-08-23 Ferro Corporation Lyophilization method and apparatus for producing particles
US7083748B2 (en) * 2003-02-07 2006-08-01 Ferro Corporation Method and apparatus for continuous particle production using supercritical fluid
US7455797B2 (en) * 2003-02-28 2008-11-25 Ferro Corporation Method and apparatus for producing particles using supercritical fluid
CN100434133C (zh) * 2003-04-29 2008-11-19 欧加农股份有限公司 反溶剂凝固方法
US20060008531A1 (en) * 2003-05-08 2006-01-12 Ferro Corporation Method for producing solid-lipid composite drug particles
EP1624862B1 (en) 2003-05-08 2014-12-31 Nektar Therapeutics Particulate materials
WO2005022603A2 (en) * 2003-09-02 2005-03-10 Integral Technologies, Inc. Low cost conductive containers manufactured from conductive loaded resin-based materials
GB0602637D0 (en) * 2006-02-09 2006-03-22 Glaxo Group Ltd Novel process
NL1031224C2 (nl) * 2006-02-23 2007-09-03 Friesland Brands Bv Het bereiden van gedroogde deeltjes met behulp van een superkritisch medium.
US20080095856A1 (en) * 2006-05-12 2008-04-24 Jacobson Gunilla B Encapsulated Nanoparticles for Drug Delivery
FR2900845B1 (fr) 2006-05-15 2009-03-06 Commissariat Energie Atomique Procede et dispositif de synthese de particules organiques ou inorganiques enrobees
EP1913955A1 (en) 2006-10-19 2008-04-23 Gerhard, Markus Novel method for treating H.pylori infections
US7745566B2 (en) * 2007-01-23 2010-06-29 Ferro Corporation Methods for the purification of polymers
US20080260852A1 (en) * 2007-01-23 2008-10-23 Ferro Pfanstiehl Laboratories, Inc. Supercritical fluid extraction produced by in-line homogenization
CA2677838C (en) 2007-02-11 2017-08-01 Map Pharmaceuticals, Inc. Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
GB0711680D0 (en) * 2007-06-18 2007-07-25 Prosonix Ltd Process
EP3272354A1 (en) 2016-07-20 2018-01-24 Technische Universität München Agents and methods for the prevention or treatment of h. pylori infections
KR102170146B1 (ko) * 2019-03-05 2020-10-26 서울대학교산학협력단 Pca 공정을 이용한 배양액의 결정화 장치 및 방법

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639441A (en) * 1992-03-06 1997-06-17 Board Of Regents Of University Of Colorado Methods for fine particle formation

Also Published As

Publication number Publication date
IS5656A (is) 2000-10-11
CA2327522A1 (en) 1999-10-21
DK1069890T3 (da) 2006-08-28
SE9801287D0 (sv) 1998-04-14
NZ507190A (en) 2002-02-01
NO20005150D0 (no) 2000-10-13
CZ20003784A3 (cs) 2001-08-15
HUP0102305A3 (en) 2003-04-28
BR9909636A (pt) 2000-12-19
AU744874B2 (en) 2002-03-07
US6372260B1 (en) 2002-04-16
SK14112000A3 (sk) 2001-07-10
IL138635A0 (en) 2001-10-31
ATE329580T1 (de) 2006-07-15
AR019262A1 (es) 2002-02-13
AU4066399A (en) 1999-11-01
DE69931904T2 (de) 2006-12-21
CN1201728C (zh) 2005-05-18
TR200002960T2 (tr) 2000-12-21
PL344077A1 (en) 2001-09-24
JP2002511400A (ja) 2002-04-16
KR20010042660A (ko) 2001-05-25
CY1105154T1 (el) 2010-03-03
CN1309555A (zh) 2001-08-22
DE69931904D1 (de) 2006-07-27
HUP0102305A2 (hu) 2001-12-28
NO329145B1 (no) 2010-08-30
NO20005150L (no) 2000-12-08
RU2208435C2 (ru) 2003-07-20
WO1999052507A1 (en) 1999-10-21
EP1069890A1 (en) 2001-01-24
EP1069890B1 (en) 2006-06-14
ES2267268T3 (es) 2007-03-01
PT1069890E (pt) 2006-09-29
CA2327522C (en) 2008-03-25
TW542724B (en) 2003-07-21
KR100600691B1 (ko) 2006-07-19
EE200000595A (et) 2002-04-15
ID29286A (id) 2001-08-16

Similar Documents

Publication Publication Date Title
ZA992549B (en) Incorporation of active substances in carrier matrixes.
IN1998CH01442A (en) Microparticles containing agricultural active ingredients
HUP0104578A3 (en) Nonsteroidal antiinflammatories and compounds being their active ingredients
HUP0001682A3 (en) Fungicide active substance combinations
ZA985867B (en) Triazole compounds and their use.
ZA991946B (en) Pyrazolopyrimidines and pyrazolotriazines.
AU7908098A (en) Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones
AU5270499A (en) Formulations having probiotically active microorganisms
EP1067130A4 (en) TRIAZOLO DERIVATIVES, AND CHIMIOKIN INHIBITORS CONTAINING THESE DERIVATIVES AS ACTIVE INGREDIENT
GB9827964D0 (en) Active backplane circuitry
EP1148107A4 (en) COATED BIOLOGICALLY ACTIVE GRAINS
PL349393A1 (en) Sulphonyloxazolamines as therapeutic active ingredients
ZA200006020B (en) Voacamine as anti-malarial agent and anti-malarial agent containing voacamine.
EP1251150A4 (en) GRAFT COPOLYMER AND WATER-RESISTANT AND WATER-REPELLENT COMPOSITION OF SOLUTION CONTAINING THIS COPOLYMER
HK1040882A1 (zh) 殺菌活性物質組合物
ZA200109989B (en) Pharmaceutical composition containing sibutramine and orlistat.
ZA9810759B (en) Proliferatively active product for treating proliferating cells.
AU3538699A (en) Novel physiologically active substances
GB9807586D0 (en) Enzymes and their use
GB9603431D0 (en) Immunodulating active substance
SI1069890T1 (sl) Vkljucitev aktivnih substanc v matriko nosilca
GB9827901D0 (en) Active semiconductor
AU2162900A (en) Microparticles containing water insoluble active agents
SG73641A1 (en) Ethylene-alpha-olefin-nonconjugated polyrene random
ZA985674B (en) Microparticles containing agricultural active ingredients